PharmiWeb

First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

First two GMP doses of rese-cel manufactured on the Cell Shuttle™ met all release specifications, were delivered on time, and ...
PharmiWeb

Think Advisors’ R&D Tax Credit Services Practice Joins Crete Professionals Alliance, Expanding Specialized Capabilities Across the Network

Think Advisors, LLC (“Think”), a national tax consulting firm, today announced that its R&D Tax Credit Services practice has ...
PharmiWeb

QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel

QIAstat-Dx BCID GPF Plus AMR Panel detects gram-positive bacteria, fungi and key antimicrobial resistance markers from ...
PharmiWeb

AdaptHealth Corp. Announces First Quarter 2026 Earnings Release Date and Conference Call

AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and ...
PharmiWeb

Action Behavior Centers Partners with the Eagles Autism Foundation, Sponsoring the Sensory Kids Zone at This Year's Eagles Autism Challenge

PHILADELPHIA, PA / ACCESS Newswire / April 14, 2026 / Action Behavior Centers, a leading provider of evidence-based applied behavior analysis (ABA) therapy for children diagnosed with autism spectrum ...
PharmiWeb

Avant Brands Reports Q1 2026 Results Highlighted by 37% Growth in Recreational Revenue

KELOWNA, BC / ACCESS Newswire / April 14, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU)("Avant" or the "Company"), a leading producer of innovative and award-winning cannabis products, ...
PharmiWeb

RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, ...
PharmiWeb

IMPLANET Reports Q1 2026 Revenue of €3.03 Million, up 18%

Revenue growth of +18% compared with Q1 2025Strong momentum in the United States, +167% in Q1 2026Business supported by the expansion of medical equipment distribution, particularly the ultrasonic ...
PharmiWeb

Rising Interest in Drug Repurposing Brings Renewed Attention to Fenbendazole as Consumer Awareness Expands in 2026

As scientific research explores legacy compounds, companies like BP Life highlight growing demand for high-purity sourcing ...
PharmiWeb

Dyve Biosciences and Moffitt Cancer Center Report Promising Study Results for First-of-Its-Kind Topical Therapy Targeting Tumor Acidity

Novel therapy that works throughout the body boosted immune response and slowed tumor growth in early studies, pointing to a potential breakthrough treatment approachCAMARILLO, Calif.--(BUSINESS WIRE) ...
PharmiWeb

CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates

CrossBridge Bio’s pipeline includes a potential best-in-class TROP2-targeting TOP1i/ATRi dual-payload ADC anticipated to enter the clinic in 2026Acquisition provides an innovative synergistic dual ...
PharmiWeb

ImmuVia Selects Quantori’s Q-Scientist Platform to Accelerate Development of First-in-Class Cancer Therapy

ImmuVia Inc., a biotechnology company developing first-in-class therapies for solid tumors, today announced that it has selected Quantori, a leading provider of digital transformation services and ...